26.11.2012 - Immunologists from Germany prove that messenger RNA vaccines work in mice, ferrets and pigs. Translation to humans would speed up flu control.
The idea sounds compelling: Instead of injecting peptide parts or complete proteins to trigger immune reactions, future vaccines could consist of messenger RNA molecules. Scientists from the Friedrich-Loeffler-Institut and the biotech enterprise CureVac GmbH (both from Tübingen, Germany) as well as from a branch of Friedrich-Loeffler-Institut on an island in the Baltic Sea near Greifswald, showed that immunisation with mRNA works thus far in mice, ferrets and pigs. The corresponding study was published online on 25 November by Nature Biotechnology. Lead author Lothar Stitz from Greifwald and colleagues report that the resulting immune responses were similar or even stronger than those provoked by commercially available vaccines.
Producing conventional vaccines is a time-consuming process. If Stitz’ approach also works in humans, flu vaccines could be designed and made within weeks instead of months. Hence, pandemics could be brought under control much more easily. What is more, mRNA vaccines in general are characterised by superior stabilities at high temperatures and by improved efficacy in young and old mice. These features could make a difference as it is mostly the elderly and children who suffer most from flu casualties.
The results strengthen German Curevac GmbH, the manufacturer of mRNA-coded antigens. Only in September, the biotech set a German record by closing the biggest financing round of a German biotech ever (€80m).
25.11.2014 The European biotech IPO slump has finally come to an end. A brand new industry report shows that compared to previous years, the number of biotech IPOs more than doubled in 2014, with London and Paris exchanges leading the pack.
19.11.2014 It’s not every day that a company is pushed into the top ten of its sector, but that day has come for Actavis. Christmas came early for the new pharma giant after completing a US$66bn (€53bn) takeover battle for the Botox manufacturer Allergan.
18.11.2014 Merck KGaA and US rival Pfizer have signed a immuno-oncology alliance worth billions: Merck will share the development and commercialisation of its cancer antibody with its US partner – for €2.3bn.
14.11.2014 Cosily coinciding with World Diabetes Day on 14th November, French biopharma Les Laboratories Servier has struck a US$1bn deal with US pharma Intarcia Therapeutics for the exclusive rights to Intarcia’s unprecedented therapy for type 2 diabetes.
12.11.2014 Glitz and glamour are not words often used to describe science and mathematics. But once a year, celebrities from the science and showbiz world come together at the Breakthough Prizes, a glitzy television bash that honours scientists for their achievements. French life scientist Emmanuelle Charpentier was among this year’s winners.
04.11.2014 Galecto Biotech has entered an agreement with Bristol-Myers Squibb for the acquisition of the company and its lead drug, providing the Swedish company with the potential of reaching over US$400m.